Health Care • Biotechnology: Pharmaceutical Preparations
$22.36 ▼ -0.68
(-2.95%)
MKT CAP: $2.51B • VOL: 648.5K
52W L $16 52W H $28
ZLAB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $457.2M | $397.6M | $266.7M |
| YoY Revenue Growth % | +15.0% | +49.1% | — |
| Gross Profit | $266.7M | $250.5M | — |
| Gross Margin % | 58.3% | 63.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$229.4M | -$282.1M | -$366.6M |
| Operating Margin % | -50.2% | -71.0% | -80.0% |
| Net Income (GAAP) | -$175.5M | -$257.1M | -$334.6M |
| EBITDA (Normalized) | -$223.0M | -$277.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$150.8M | -$214.9M | -$198.2M |
| Capital Expenditures (CapEx) | $8.1M | $5.7M | — |
| Free Cash Flow (FCF) | -$158.9M | -$220.5M | -$198.2M |
| FCF Margin % | -34.8% | -55.5% | -74.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $679.6M | $449.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $715.5M | $840.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZLAB.